The combination of a massive EPS miss and a restatement of prior-period financials creates significant near-term overhang. Monitor the restatement details and any potential impact on the Horizon loan facility covenants. The strong Zelsuvmi unit growth provides a fundamental floor, but the accounting issues and cash burn rate (~$8M/quarter) warrant caution until the restated Q1 2026 numbers are filed.
Price Chart
Executive Summary
Pelthos Therapeutics reported Q2 2026 revenue of $15.4M (up 45% QoQ) driven by strong Zelsuvmi prescription growth, but GAAP EPS of -$6.62 missed the consensus estimate of -$2.95 by a wide margin. The company also disclosed a restatement of its Q1 2026 financials (Item 4.02), adding accounting uncertainty. While the commercial launch is accelerating, the deep EPS miss and restatement overshadow the top-line beat, making this a bearish report for the stock.
Key Financial Metrics
Key Facts
- Zelsuvmi net product revenue grew 45% QoQ to $15.4M in Q2 2026 from $10.7M in Q1 2026.
- 11,925 Zelsuvmi units were dispensed in Q2 2026, a 48% QoQ increase.
- GAAP EPS of -$6.62 missed the consensus estimate of -$2.95 by 124.6%.
- The 8-K filing references a prior Item 4.02 filing that restates Q1 2026 financials.
- Cash balance fell to $24.2M at June 30, 2026, from $32.0M at March 31, 2026.
- Stockholders' equity turned negative to -$1.5M at June 30, 2026, from +$38.9M at Dec 31, 2025.
- Adjusted EBITDA improved to -$5.7M in Q2 2026 from -$8.0M in Q1 2026.
- SG&A expenses rose 31% QoQ to $27.7M, including $5.3M in non-recurring milestones.
Financial Impact
GAAP EPS miss of 124.6% vs consensus ($-6.62 actual vs $-2.95 estimate); revenue beat of 1.3% ($15.4M actual vs $15.2M estimate).
Risk Factors
- Restatement of Q1 2026 financials introduces accounting and credibility risk.
- Cash burn of ~$8M/quarter (Adjusted EBITDA) with only $24.2M cash on hand implies limited runway without additional financing.
- Stockholders' equity turned negative, which could trigger debt covenant concerns.
- Heavy SG&A spend ($27.7M in Q2) may not be sustainable relative to current revenue scale.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001919246-26-000112 |
| Document: pths-20260813.htm | 0001919246-26-000112 |
| Document: investmentdeck_202608xex.htm | 0001919246-26-000112 |
| Document: 0001919246-26-000112-index-headers.html | 0001919246-26-000112 |
| Document: 0001919246-26-000112-index.html | 0001919246-26-000112 |
| Document: 0001919246-26-000112.txt | 0001919246-26-000112 |
| 8-K Data (Synthetic) | 0001919246-26-000112 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 24d ago | 8-K | $20.60 $20.50 | ▼ −0.49% | ▼ −1.65% | $17.01 (−17.43%) |
Aug 13, 2026 10w ago | 8-K | $28.95 $26.66 | ▲ +7.91% | ▲ +5.95% | $17.01 (+41.24%) |
Aug 3, 2026 12w ago | Press Release | $26.84 | awaiting T+5 | — | $17.01 (−36.62%) |
Jun 17, 2026 18w ago | Insider Cluster | $29.00 $29.21 | ▲ +0.72% | ▲ +2.39% | $17.01 (−41.34%) |
May 28, 2026 21w ago | 8-K | $26.47 $25.55 | ▼ −3.48% | ▼ −0.95% | $17.01 (−35.74%) |
May 22, 2026 22w ago | 144 | $26.66 $26.20 | ▼ −1.73% | ▼ −3.40% | $17.01 (−36.20%) |
May 21, 2026 22w ago | 8-K | $26.66 $26.20 | ▲ +1.73% | ▲ +3.38% | $17.01 (+36.20%) |
May 14, 2026 23w ago | 8-K | $27.69 $27.10 | ▼ −2.13% | ▼ −1.41% | $17.01 (−38.57%) |
May 14, 2026 23w ago | Press Release | $27.69 $27.10 | ▼ −2.13% | ▼ −1.41% | $17.01 (−38.57%) |
Apr 20, 2026 26w ago | 3 | $23.00 $24.97 | ▲ +8.57% | ▲ +7.48% | $17.01 (−26.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers